Stoimen Dimitrov Dimitrov

Dr. Stoimen Dimitrov Dimitrov

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2026 in Antibodies
Verified
Journal Article
Open access
PDF file
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
MTMihael Emilov Tsalta-Mladenov
Mihael Emilov Tsalta-Mladenov
PKPlamena Kabakchieva
Plamena Kabakchieva
TGTsvetoslav Georgiev
Tsvetoslav Georgiev
SASilva Andonova
Silva Andonova
Paraneoplastic neurological syndromes (PNSs) are immune-mediated disorders caused by an antitumor response that cross-reacts with the nervous system, leading to severe and often irreversible neurological disability. Once considered exceedingly rare, PNSs are now increasingly recognized owing to the identification of novel neural autoantibodies, wider use of commercial testing, and the emergence of immune checkpoint inhibitor (ICI)-related neurotoxicity that phenotypically overlaps with classic PNS. In this narrative review, we performed a structured search of PubMed/MEDLINE, Scopus, Web of Science, and Google Scholar, without date restrictions, to summarize contemporary advances in the epidemiology, pathogenesis, diagnosis, and management of PNS. Population-based data show rising incidence, largely reflecting improved ascertainment and expanding indications for ICIs. Pathogenetically, we distinguish T-cell-mediated syndromes associated with intracellular antigens from antibody-mediated disorders targeting neuronal surface proteins, integrating emerging concepts of molecular mimicry, tumor genetics, and HLA-linked susceptibility. The 2021 PNS-Care criteria are also reviewed, which replace earlier “classical/non-classical” definitions with risk-stratified phenotypes and antibodies, and demonstrate superior diagnostic performance while underscoring that “probable” and “definite” PNS should be managed with equal urgency. Newly described antibodies and methodological innovations such as PhIP-Seq, neurofilament light chain, and liquid biopsy are highlighted, which refine tumor search strategies and longitudinal monitoring. Management principles emphasize early tumor control, prompt immunotherapy, and a growing repertoire of targeted agents, alongside specific considerations for ICI-associated neurological syndromes. Remaining challenges include diagnostic delays, limited high-level evidence, and the paucity of validated biomarkers of disease activity. Future work should prioritize prospective, biomarker-driven trials and multidisciplinary pathways to shorten time to diagnosis and improve long-term outcomes in patients with PNS.

30 September 2024 in Anti-Aging Eastern Europe
Verified
Journal Article
Open access
PDF file
TGTsvetoslav Georgiev
Tsvetoslav Georgiev
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
PKPlamena Kabakchieva
Plamena Kabakchieva
Background: Osteoarthritis (OA) is a prevalent musculoskeletal disorder, often complicated by comorbid conditions such as cardiovascular diseases, metabolic syndromes, and mental health issues. These comorbidities significantly impact the progression of OA and the effectiveness of its management, posing challenges for comprehensive patient care. Objectives: This review examines the relationship between OA and its common comorbidities, focusing on cardiovascular diseases, metabolic conditions, and mood disorders. We also explore the impact of pharmacological and non-pharmacological treatments in these patients, emphasizing the importance of integrated care strategies. Methods: Data from multiple studies were analyzed to assess the association between OA and comorbid conditions. The studies examined mortality risk, cardiovascular incidents, metabolic syndrome, diabetes, obesity, and mood disorders, while considering the effects of various OA treatment modalities, particularly non-steroidal anti-inflammatory drugs (NSAIDs). Results: Cardiovascular comorbidities, including coronary heart disease, are significantly linked to OA, with functional limitations such as impaired mobility being major contributors to increased cardiovascular risks and mortality. NSAIDs, commonly prescribed for OA, present substantial cardiovascular and renal risks, complicating their use in patients with pre-existing cardiovascular conditions. Metabolic comorbidities, particularly obesity and diabetes, are highly prevalent in OA patients and are associated with reduced quality of life and exacerbation of OA symptoms. Furthermore, mood disorders like depression and anxiety are common among OA patients, leading to a vicious cycle of pain and psychological distress that worsens functional outcomes. Conclusions: OA is closely related to various comorbidities, necessitating a holistic, multimodal approach to treatment. Beyond pharmacologic interventions, lifestyle changes, psychosocial support, and careful management of comorbid conditions are essential for improving outcomes in OA patients.

31 October 2025 in Applied Sciences
Verified
Journal Article
Open access
PDF file
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
SBSimona Bogdanova
Simona Bogdanova
ZAZhaklin Apostolova
Zhaklin Apostolova
BKBoryana Kasapska
Boryana Kasapska
PKPlamena Kabakchieva
Plamena Kabakchieva
TGTsvetoslav Georgiev
Tsvetoslav Georgiev
Artificial intelligence (AI) is rapidly transforming rheumatology, particularly in imaging and laboratory diagnostics where data complexity challenges traditional interpretation. This narrative review summarizes current evidence on AI-driven tools across musculoskeletal ultrasound, radiography, MRI, CT, capillaroscopy, and laboratory analytics. A structured literature search (PubMed, Scopus, Web of Science; 2020–2025) identified 90 relevant publications addressing AI applications in diagnostic imaging and biomarker analysis in rheumatic diseases, while twelve supplementary articles were incorporated to provide contextual depth and support conceptual framing. Deep learning models, notably convolutional neural networks and vision transformers, have demonstrated expert-level accuracy in detecting synovitis, bone marrow edema, erosions, and interstitial lung disease, as well as in quantifying microvascular and structural damage. In laboratory diagnostics, AI enhances the integration of traditional biomarkers with high-throughput omics, automates serologic interpretation, and supports molecular and proteomic biomarker discovery. Multi-omics and explainable AI platforms increasingly enable precision diagnostics and personalized risk stratification. Despite promising performance, widespread implementation is constrained by significant domain-specific validation gaps, data heterogeneity, lack of external validation, ethical concerns, and limited workflow integration. Clinically meaningful progress will depend on transparent, validated, and interoperable AI systems supported by robust data governance and clinician education. The transition from concept to clinic is under way—AI will likely serve as an augmenting rather than replacing partner, standardizing interpretation, accelerating decision-making, and ultimately facilitating precision, data-driven rheumatologic care.

30 April 2024 in Rheumatology
Verified
Journal Article
Open access
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
GGGeorgi Gerganov
Georgi Gerganov
Simona Bogdanova-PetrovaSimona Bogdanova-Petrova
Simona Bogdanova-Petrova
SHSvetlana Hristova
Svetlana Hristova
RMRosina Moraliyska
Rosina Moraliyska
TGTsvetoslav Georgiev
Tsvetoslav Georgiev
Rapidly destructive coxopathy (RDC) is a rare type of coxarthritis marked by swift deterioration of the hip joint. Although its cause remains unclear, several pathophysiological mechanisms are proposed. To comprehensively analyze this poorly understood condition, a literature search was conducted focusing on associations of bilateral RDC and rheumatoid arthritis (RA). The problem of long-standing RA, bilateral RDC with a febrile episode that preceded a rapid decline in mobility and severe hip pain, with radiological assessment confirmed bilateral hip destruction, was presented. Rapidly destructive coxopathy, especially when linked to RA, poses diagnostic and therapeutic challenges. Our review confirmed by the clinical picture emphasizes the need for vigilance in RA patients with hip involvement and calls for further research to understand RDC’s mechanisms and enhance clinical care.

30 June 2026 in Rheumatology (Bulgaria)
Verified
Journal Article
Open access
PDF file
TGTsvetoslav Georgiev
Tsvetoslav Georgiev
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
KBKonstantin Batalov
Konstantin Batalov
ZBZguro Batalov
Zguro Batalov
RKRositsa Karalilova
Rositsa Karalilova
ABAnastas Batalov
Anastas Batalov
Rheumatoid arthritis-associated interstitial lung disease [RA-ILD] requires more than a radiological diagnosis. A usual interstitial pneumonia pattern describes pulmonary architecture, but does not by itself establish whether disease is progressing, which component is modifiable, or how safely treatment can be deferred. This narrative review revisits the disease-behaviour approach and distinguishes susceptibility to ILD, prognosis after ILD develops, and prediction of treatment benefit. It integrates contemporary classification and guidance with evidence from immunomodulatory cohorts, INBUILD, TRAIL1 and FIBRONEER-ILD. We propose a reserve-aware interpretation of trajectory: structural burden and the pace of deterioration should be considered alongside remaining physiological reserve, competing hazards and the likely cost of waiting. This is a clinical reasoning framework, not a validated score. Progressive pulmonary fibrosis provides a useful operational definition, but should neither be mistaken for proof of an exclusively fibrotic mechanism nor become a prerequisite for treating already consequential lung disease. Molecular advances, including MUC5B, telomere length and protein signatures, illustrate the distance between biological plausibility and treatment selection. Antifibrotic evidence supports slowing functional loss; newer survival analyses require careful separation of overall pulmonary fibrosis populations from RA-specific inference. The therapeutic objective is therefore not to treat an imaging label or normalise an isolated measurement, but to preserve useful lung function while controlling systemic disease and limiting treatment-related harm.

29 June 2026 in Applied Sciences
Verified
Journal Article
Open access
PDF file
DPDaliya Tsvetanova Pencheva
Daliya Tsvetanova Pencheva
Stoimen Dimitrov DimitrovStoimen Dimitrov Dimitrov
Stoimen Dimitrov Dimitrov
NSNikolay Stoilov
Nikolay Stoilov
MIMariana Ivanova
Mariana Ivanova
Systemic lupus erythematosus (SLE) is a chronic, heterogeneous autoimmune disease characterized by multisystem involvement and substantial morbidity. Although survival has improved over recent decades, disease burden remains considerable due to cumulative organ damage, comorbidities, and treatment-related toxicity, particularly from long-term glucocorticoid use. Advances in the understanding of SLE immunopathogenesis have led to the development of targeted therapies. Currently approved agents include belimumab and anifrolumab, while obinutuzumab has been approved for lupus nephritis and has also demonstrated significant efficacy in phase III trials in SLE. Several additional agents are in late-stage clinical development, including litifilimab (targeting plasmacytoid dendritic cells), telitacicept and ianalumab (BAFF/APRIL and B-cell modulation), dapirolizumab pegol (CD40L blockade), deucravacitinib and upadacitinib (TYK2/JAK inhibition), and cenerimod (S1P11 modulation). This narrative review summarizes current phase III evidence and emerging therapeutic strategies, highlighting the ongoing transition toward precision medicine and individualized treatment approaches in SLE.